FY2024 · ended Dec 31, 2024 · Revenue $157,220, +468.6% YoY · Filed Mar 18, 2025
Zivo Bioscience, Inc. (ZIVO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $157,220 and a net loss of $13.4 million. As of Sep 30, 2025 it held $57,222 in cash and investments and $285,837 in total debt.
Revenue (TTM)
$209,025
+164.5% vs year-ago TTM
Net income (TTM)
$-8.49M
+38.0% vs year-ago TTM
Operating cash flow (TTM)
$-3.08M
+25.3% vs year-ago TTM
Free cash flow
—
EPS
$-4.23
Dividend per share
$3.11
Shares outstanding
3.76M
+35.3% vs prior year
Net cash
$-228,615
as of Sep 30, 2025
Operating margin
-4045.7%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZIVO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Bloomfield Hills, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1101026
- Former names
- HEALTH ENHANCEMENT PRODUCTS INC (until Oct 16, 2014); WESTERN GLORY HOLE INC (until Jan 26, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $157,220 | $27,650 | $0 | $0 | $20,000 |
| Operating income | -$13.4M | -$7.3M | -$8.7M | -$8.6M | -$8.6M |
| Net income | -$13.4M | -$7.8M | -$8.7M | -$8.8M | -$9.1M |
| Diluted EPS | -$4.23 | — | — | — | — |
| Operating cash flow | -$4.3M | -$5.8M | -$7.1M | -$6.8M | -$2.6M |
| Total assets | $1.6M | $555,715 | $2.1M | $9.0M | $220,179 |
| Total liabilities | $2.2M | $2.8M | $2.1M | $2.9M | $11.5M |
| Stockholders' equity | -$514,897 | -$2.2M | -$10,622 | $6.0M | -$11.3M |
| Cash and investments | $1.5M | $274,380 | $1.8M | $8.9M | $137,862 |
| Total debt | $0 | $106,342 | $205,178 | $15,178 | $44,350 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 30, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Dec 23, 2025 | Dec 19, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 10, 2025 | Sep 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 18, 2025 | Aug 12, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
All 757 Zivo Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.